Stay ADvised: NAD Sniffs Out Puffery, Scrutinizes Surveys & Weighs in on "#1"
In This Issue:
- Elanco Itches to Challenge PetIQ Flea & Tick Collar Claims at NAD
- NAD Looks to EPA Guidance When Evaluating Health Efficacy Claims
- SuperBeets vs. Total Beets: Battle Over Whether Unit or Dollar Sales Data Is "#1" at Fast-Track SWIFT NAD
- NAD Smells Puffery in Sunscreen Challenge
Elanco Itches to Challenge PetIQ Flea & Tick Collar Claims at NAD
Recently, the National Advertising Division (NAD) considered a challenge between competitors in the flea-and-tick collar market. Elanco, which markets the Seresto flea-and-tick collar for dogs and cats, alleged that PetIQ's advertising for its PetArmor Extend collar conveyed several unsupported messages. PetIQ countered that its claims were either non-actionable puffery or adequately substantiated.
NAD first addressed PetIQ's professional recommendation claim that PetArmor contains "#1 Vet-Recommended Ingredients." It concluded that consumers would reasonably understand the claim to mean that competent and reliable evidence demonstrates veterinarians recommend the imidacloprid and flumethrin active ingredient combination more than any other competing flea-and-tick collar formulas—not that veterinarians recommend every ingredient in the product, including inactive ingredients. PetIQ supported the claim with a survey of practicing veterinarians, and although Elanco challenged several aspects of the survey, NAD concluded it was a sufficiently reliable fit for the advertising claim. For example, Elanco criticized the survey for using a closed list of ingredient combinations without write-in options. NAD acknowledged that limitation but concluded it was not fatal because the survey measured recommendations among multiple marketed formulas and produced a decisive result, with nearly 90% of veterinarians selecting the imidacloprid/flumethrin combination. Elanco also argued that asking veterinarians which formulas they "would recommend" was too hypothetical under prior NAD precedent. NAD distinguished those earlier cases, explaining that the survey did not ask veterinarians whether they would recommend the advertised product after reviewing promotional materials, but instead asked them to choose among existing flea-and-tick collar formulas. In that context, the "would recommend" wording was sufficiently probative of veterinarians' professional preferences.
NAD also considered PetIQ's claim that PetArmor Extend "Lasts 2 months longer than competing collars*" that appears on PetIQ's product webpage for PetArmor Extend. Elanco argued that consumers would understand the claim as inviting a comparison to Seresto, even though Seresto was not named. NAD agreed. Looking at the advertising as a whole—including marketing positioning PetArmor as a lower-priced alternative to Seresto—it concluded that reasonable consumers would understand "competing collars" to include Seresto. NAD recommended that PetIQ discontinue or modify the claim to avoid conveying that PetArmor Extend lasts longer than Seresto (which lasts 8 months just like PetIQ) or competing collars generally. The decision serves as another reminder that comparative claims can encompass unnamed competitors when the surrounding context makes the comparison apparent.
Finally, NAD addressed PetIQ's claim that "with season-to-season coverage" consumers can have "peace of mind knowing your dog is shielded with the hardest working collar that money can buy." PetIQ argued that this language was puffery. NAD disagreed. Although the phrase might constitute puffery in isolation, the surrounding advertising tied it to objective performance messages about seasonal protection, causing consumers to understand it as a superiority claim. PetIQ argued that the claim was supported because PetArmor contains the same active ingredients as Seresto, lasts eight months, and costs less. NAD concluded that this evidence supported, at most, a value proposition—not the broader superiority message that PetArmor Extend is more effective and "the hardest working collar that money can buy."
Key Takeaways
This decision offers useful guidance on survey design, comparative advertising, and puffery. First, professional recommendation surveys need not be perfect, but they should closely fit the advertising claim and measure real-world professional preferences rather than hypothetical reactions to marketing. Second, advertisers should remember that unnamed competitor comparative claims may still be understood as referring to the obvious market leader when the surrounding advertising points consumers in that direction. Finally, superlative language should never be evaluated in isolation. Even classic puffery can become an objective superiority claim when it appears alongside measurable performance claims.
NAD Looks to EPA Guidance When Evaluating Health Efficacy Claims
To what extent may the National Advertising Division (NAD) rely on federal regulatory guidance that is not binding on the organization? That question arose recently when Professional Disposables International (PDI) challenged claims made by AceJan Capital, a competitor in the market for disinfection products used in hospitals and healthcare facilities. PDI markets EPA-registered surface disinfectants and wipes for use against Clostridioides difficile (C. diff.), a notoriously difficult-to-kill pathogen that can cause serious infections in healthcare settings. AceJan, meanwhile, markets an on-site hypochlorous acid (HOCl) generator and claimed that its product kills C. diff. in five minutes.
AceJan first argued that NAD lacked jurisdiction because the challenged materials were directed to sophisticated hospital personnel rather than the general public. NAD quickly rejected that argument, reiterating that advertising directed to healthcare professionals is still subject to self-regulation and that audience sophistication does not diminish an advertiser's obligation to disseminate truthful, accurate, and substantiated claims. AceJan also argued that statements appearing on product canisters and in training materials were not advertising because they were provided only after purchase. NAD disagreed, concluding that the challenged statements described the product's efficacy and were intended to persuade healthcare facilities and personnel of the product's value.
On the merits, AceJan relied primarily on a laboratory study evaluating its HOCl solution against C. diff. spores. NAD acknowledged that the study contained several indicia of reliability. Nevertheless, it looked to the EPA's testing protocols as persuasive guidance for determining whether the study constituted competent and reliable scientific evidence. Although the EPA's protocols are not legally binding on NAD, they provide detailed scientific guidance for evaluating claims of this nature. Applying those principles, NAD concluded that the record lacked important information concerning issues such as spore preparation, purity, and testing methodology—details necessary to determine whether the study had subjected the product to a sufficiently rigorous C. diff. challenge. Without that information, NAD concluded that the evidence did not adequately support the challenged biological efficacy claims.
Key Takeaways
Although federal regulatory guidance does not formally bind NAD, this decision demonstrates that where an agency has developed detailed scientific standards for evaluating a particular type of efficacy claim, NAD may look to those standards when determining whether an advertiser possesses competent and reliable scientific evidence. Advertisers should therefore consider not only what evidence they have, but also whether that evidence would satisfy the scientific expectations reflected in applicable regulatory guidance.
SuperBeets vs. Total Beets: Battle Over Whether Unit or Dollar Sales Data Is "#1" at Fast-Track SWIFT NAD
Force Factor Brands advertises its beet-based dietary supplement Total Beets as "America's #1 Best-Selling Beets Brand," the "#1 Best Selling Beets Brand in America," and the "#1 Beets Brand in America." Competitor Humann, which markets SuperBeets, challenged these claims in a single issue Fast-Track SWIFT proceeding before the National Advertising Division.
The dispute centered on whether unit sales or dollar sales provided the appropriate metric for substantiating the challenged "#1" claims. Although the parties agreed that Force Factor sold more units than Humann, Humann argued that dollar sales better reflected marketplace leadership because the competing products are sold in different forms, package sizes, and at different price points. NAD rejected that argument. Consistent with longstanding precedent, it concluded that nothing in the record justified departing from NAD's customary reference to number of units sold for evaluating sales ranking claims. Although the products differed in size, form, and price, the evidence did not demonstrate that those differences distorted the unit-sales comparison or that dollar sales more accurately reflected the message consumers would take away from the advertising.
NAD next considered whether Force Factor had relied on stale data. Advertisers have an ongoing obligation to support superiority claims with current sales data, and Force Factor acknowledged that some citations in its advertising had not been updated. However, the company submitted current syndicated sales data during the proceeding demonstrating that it continued to lead Humann in unit sales, providing a reasonable basis for the challenged claims.
Finally, NAD distinguished between claims that naturally communicate unit sales and broader "#1" claims. Consumers would ordinarily understand "best-selling" to refer to units sold, making additional disclosure unnecessary. However, the broader claim "#1 Beets Brand in America" does not explicitly reference sales. NAD therefore recommended that Force Factor disclose that the "#1" ranking is based on total unit sales.
Key Takeaways
NAD reaffirmed its longstanding preference for unit sales as the appropriate metric for substantiating "#1" sales claims, while emphasizing that the conclusion was based on the record before it. At the same time, the decision highlights the importance of making clear what a "#1" claim actually measures. Claims expressly referring to "best-selling" naturally communicate unit sales, but broader market leadership claims may require advertisers to disclose that the ranking is based on units sold rather than some other undisclosed metric.
NAD Smells Puffery in Sunscreen Challenge
It was probably only a matter of time before Vacation Inc.'s distinctive marketing style attracted an NAD challenge. Rather than emphasizing skincare benefits or SPF performance, Vacation leans heavily into nostalgic 1980s beach culture and advertises its sunscreen as the "World's Best-Smelling Sunscreen." Competitor Beiersdorf, maker of Nivea sunscreen, challenged the claim as unsupported.
Beiersdorf argued that scent is a measurable product attribute and therefore claims about fragrance require substantiation. NAD agreed that scent can be measured, but explained that consumers would not reasonably expect an advertiser to have compared the smell of every sunscreen in the world to substantiate a claim of being the "world's best." More importantly, while scent can be measured, fragrance preference remains inherently subjective. Considering both the subjective nature of scent and the exaggerated nature of the claim, NAD concluded that consumers would view "World's Best-Smelling Sunscreen," when presented by itself, as non-actionable puffery. Accordingly, the claim could appear on retail signage and product packaging without substantiation.
The result changed, however, when the same claim appeared on Vacation's website. There, "World's Best-Smelling Sunscreen" appeared immediately above a five-star rating, review score, and review count. In that context, consumers could reasonably interpret the claim as being supported by customer reviews rather than simply as advertising hyperbole. NAD therefore recommended that Vacation modify the website presentation to avoid conveying that its claim to be the "World's Best-Smelling Sunscreen" was substantiated by consumer reviews.
Key Takeaways
This decision illustrates once again that puffery is highly context dependent. Even claims that appear too exaggerated to be taken literally can lose their puffery protection when tied to objective cues suggesting substantiation for a claim of preference. Advertisers relying on colorful, opinion-based marketing should therefore evaluate not only the claim itself, but also the surrounding context—including ratings, reviews, and other evidence that may imply the preference claim is objectively substantiated.